Signal: AbbVie ends multi-million dollar cancer drug deal with I-Mab
The biopharma giant's decision to end its partnership with I-Mab follows it ending a trial for the drug early.
The biopharma giant's decision to end its partnership with I-Mab follows it ending a trial for the drug early.
What's Your Reaction?
